---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-010837"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2024-08-16T23:59:59+00:00"
generated_at: "2026-05-31T08:51:20.407422+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance

## Summary
- Reverse split effective Aug 20, 2024; shares outstanding drop from ~72.4M to ~1.4M.
- Authorized shares reduced from 1B to 20M; fractional shares are rounded up to whole shares.
- Split intended to raise bid price above $1.00 to meet Nasdaq continued listing requirement.
- New CUSIP 29273B 401; common stock continues trading under NDRA on Nasdaq.
- Board set ratio on Aug 8 after stockholder authorization at Aug 6 annual meeting.

## SEC filing metadata
- accession: 0001654954-24-010837
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2024-08-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495424010837/0001654954-24-010837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495424010837/endra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-010837
- JSON: https://secwatch.observer/filing/0001654954-24-010837.json
- Plain text: https://secwatch.observer/filing/0001654954-24-010837.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.